Skip to content

Omeros OMER Free cash flow

Free cash flow at other companies

Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-$44.32M+9.7%
Immunome logo
ImmunomeIMNM
-$61.64M-8.7%
Vor Biopharma logo
Vor BiopharmaVOR
-$38.29M-22.4%
Annexon logo
AnnexonANNX
-$46.8M+6.6%
Arcus Biosciences logo
Arcus BiosciencesRCUS
-$138M-3.8%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
-$28.87M-4.4%

Other financials

Income statement

See full
Revenue$9.9M
Gross profit$29.7M
Operating income-$40.9M-9.2%
Net income$56.1M+268%
EPS (diluted)-$0.59-20.4%

Balance sheet

See full
Cash & equivalents$1.9M-55.3%
Total debt$13.5M-30.3%
Total equity-$63.3M+70.3%
Total assets$286.2M+21.7%

Cash flow

See full
Operating cash flow-$14.5M+59.5%
CapEx--100%

Valuation

See full
Market cap$765.73M+307%
P/S8.5×

Profitability

See full
Gross margin98.9%
Operating margin-181.8%
Net margin-136.6%
FCF margin-121.6%

Returns & leverage

See full
Return on equity86.6%
Debt / equity0.3×-1.1×
Current ratio+1.9×

Where this comes from

Calculated from Omeros’s reported figures.

The official record: Omeros’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Omeros's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Omeros's free cash flow?
Omeros (OMER) reported free cash flow of -$14.51M in Q1 2026.
How has Omeros's free cash flow changed year-over-year?
Omeros's free cash flow increased by 59.6% year-over-year, from -$35.88M to -$14.51M.
What is the long-term trend for Omeros's free cash flow?
Over 2 years (2021 to 2025), Omeros's free cash flow has grown at a 2.8% compound annual growth rate (CAGR), from -$110M to -$116.16M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.